How we count matters – infections are a major cause of death among patients with type 2 diabetes DOI Creative Commons
Henrik Støvring, Sarah H. Wild

The Lancet Regional Health - Europe, Год журнала: 2024, Номер 48, С. 101177 - 101177

Опубликована: Дек. 11, 2024

Язык: Английский

Comment on Chwal et al. On-Target Low-Density Lipoprotein Cholesterol in Adults with Diabetes Not at High Cardiovascular Disease Risk Predicts Greater Mortality, Independent of Early Deaths or Frailty. J. Clin. Med. 2024, 13, 7667 DOI Open Access

Folkert H. van Bruggen,

Hendrika J. Luijendijk

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(8), С. 2559 - 2559

Опубликована: Апрель 8, 2025

The ELSA-Brasil study provides important insights into the association between LDL-C levels and all-cause mortality in adults with diabetes who are not at high cardiovascular risk [...]

Язык: Английский

Процитировано

1

Type 2 Diabetes Impacts the Efficacy of Syphilis Treatment and is a Risk Factor for Late Syphilis: A Retrospective Cohort Study DOI Creative Commons

Yijie Tang,

Mengxiao Wu, Wenwen Xu

и другие.

Acta Dermato Venereologica, Год журнала: 2025, Номер 105, С. adv42210 - adv42210

Опубликована: Апрель 8, 2025

This study examined the relationship between type 2 diabetes and late syphilis. A retrospective analysis was conducted, including 96 syphilis patients with 122 matched non-diabetic controls. The development of late-stage responses to initial treatment were monitored over a 2-year period. Stratified logistic regression used assess whether increased risk Differences in groups evaluated using χ2 tests Kaplan–Meier curves. cohort confirmed that serological cure rate within 12 months significantly lower diabetic patients. Type impacts efficacy is factor for

Язык: Английский

Процитировано

0

On-Target Low-Density Lipoprotein Cholesterol in Adults with Diabetes Not at High Cardiovascular Disease Risk Predicts Greater Mortality, Independent of Early Deaths or Frailty DOI Open Access

Bruna Cristine Chwal,

Rodrigo Citton Padilha dos Reis, María Inês Schmidt

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(24), С. 7667 - 7667

Опубликована: Дек. 16, 2024

Background/Objectives: Lowering low-density lipoprotein cholesterol (LDL-C) to <70 mg/dL is recommended for most patients with diabetes. However, clinical trials investigating subjects diabetes who are not at high cardiovascular risk inconclusive regarding the all-cause mortality benefit of current target, and real-world studies suggest greater mortality. We aimed assess different LDL-C levels among examine potential roles early deaths frailty this Methods: followed 2098 such participants ELSA-Brasil cohort between 2008 2019. Results: Over 10.3 (1.4) years follow-up, 204 (9.7%) individuals died. In proportional hazards models, values < 100 had adjusted compared those 100–129 (HR = 1.67; 95%CI 1.21–2.30 HR 2.27; 1.51–3.41, respectively). Increased when was <100 higher in >60 2.12; 1.35–3.34) greatest due cancer 2.55; 1.10–5.91). Further analyses that excluded phenotype 2.01; 1.19–3.41) or index 1.92; 1.17–3.16) did materially alter results. The death across spectrum U-shaped, a nadir 112.2 mg/dL. Conclusions: these within currently explained by frailty. Given recent decline increased infections persons diabetes, significance low requires reconsideration definition treatment targets warrants further trial evaluation.

Язык: Английский

Процитировано

1

How we count matters – infections are a major cause of death among patients with type 2 diabetes DOI Creative Commons
Henrik Støvring, Sarah H. Wild

The Lancet Regional Health - Europe, Год журнала: 2024, Номер 48, С. 101177 - 101177

Опубликована: Дек. 11, 2024

Язык: Английский

Процитировано

0